This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04757610
Recruitment Status : Recruiting
First Posted : February 17, 2021
Last Update Posted : November 30, 2023
Information provided by (Responsible Party):
Opthea Limited

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024